Head-To-Head Review: Amyris (AMRS) vs. Its Rivals

Amyris (NASDAQ: AMRS) is one of 25 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its competitors? We will compare Amyris to similar companies based on the strength of its analyst recommendations, valuation, dividends, risk, institutional ownership, profitability and earnings.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Amyris has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Amyris’ competitors have a beta of 0.49, suggesting that their average share price is 51% less volatile than the S&P 500.

Valuation & Earnings

This table compares Amyris and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amyris $143.45 million -$77.39 million -2.20
Amyris Competitors $3.36 billion $346.77 million 5.27

Amyris’ competitors have higher revenue and earnings than Amyris. Amyris is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Amyris and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amyris 0 1 2 0 2.67
Amyris Competitors 120 468 731 23 2.49

Amyris currently has a consensus price target of $9.67, suggesting a potential upside of 44.06%. As a group, “Industrial organic chemicals” companies have a potential upside of 13.95%. Given Amyris’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Amyris is more favorable than its competitors.


This table compares Amyris and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amyris -53.95% N/A -96.89%
Amyris Competitors -11.48% -11.21% -5.31%

Institutional and Insider Ownership

22.3% of Amyris shares are owned by institutional investors. Comparatively, 53.2% of shares of all “Industrial organic chemicals” companies are owned by institutional investors. 11.3% of Amyris shares are owned by insiders. Comparatively, 14.0% of shares of all “Industrial organic chemicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Amyris competitors beat Amyris on 9 of the 13 factors compared.

Amyris Company Profile

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply